New-onset atrial fibrillation in comorbid patients
DOI: 10.32364/2587-6821-2025-9-1-2
A.A. Nikiforov, A.S. Sinyaeva, O.V. Tikhonova, E.V. Filippov
Ryazan State Medical University, Ryazan, Russian Federation
Aim: to characterize patients with new-onset AF associated/not associated with chronic non-communicable diseases, and to evaluate levels of biological markers of myocardial fibrosis, as well as significant clinical outcomes.
Materials and Methods: 128 patients with new-onset atrial fibrillation including 50 subjects without severe chronic non-communicable diseases and 78 subjects with chronic non-communicable diseases were enrolled in the study. Complaints and medical history were recorded. Laboratory tests of myocardial fibrosis markers (transforming growth factor beta (TGF-β), galectin 3), as well as ECG, EchoCG were performed. Adverse clinical outcomes were assessed for 1 year after enrollment.
Results: at baseline, high heart rate (p=0.001), obesity (p<0.001), and hypertension (p<0.001) were significantly higher in the experimental group. According to EchoCG data, a LVEF value in the experimental group was higher than in controls (p=0.025). As for other parameters, no significant differences were reported. The levels of myocardial fibrosis markers showed significant differences between those of TGF-beta and galectin 3 in experimental and control groups (p<0.001). The experimental group demonstrated higher numbers of repeated hospitalizations (p=0.044) and fatal outcomes (p=0.042). Radiofrequency ablations were significantly higher in the experimental group (p=0.031).
Conclusions: patients with chronic non-communicable diseases had significantly more risk factors. They were more likely to develop and to worsen myocardial fibrosis (according to the marker levels measuring). Moreover, adverse clinical outcomes (repeated hospitalization, infarction, stroke, coronary angiography procedures, radiofrequency ablation, and death) were more common in them during the year.
Keywords: myocardial fibrosis markers, atrial fibrillation, comorbidity, arrhythmia, myocardial fibrosis.
For citation: Nikiforov A.A., Sinyaeva A.S., Tikhonova O.V., Filippov E.V. New-onset atrial fibrillation in comorbid patients. Russian Medical Inquiry. 2025;9(1):12–17 (in Russ.). DOI: 10.32364/2587-6821-2025-9-1-2
ABOUT THE AUTHORS:
Alexander A. Nikiforov — C. Sc. (Med.), Assistant Professor of the Department of Pharmacology, Ryazan State Medical University; 9, Vysokovol'tnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-7364-7687
Anna S. Sinyaeva — Teaching Assistant of the Department of Polyclinic Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovol'tnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-7205-5321
Oksana V. Tikhonova — C. Sc. (Phys.-Math.), Assistant Professor of the Department of Mathematics, Physics and Health Informatics, Ryazan State Medical University; 9, Vysokovol'tnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-9894-045X
Evgeny V. Filippov — Dr. Sc. (Med.), Professor, Head of the Department of Polyclinic Therapy, Preventive Medicine and General Medical Practice, Ryazan State Medical University; 9, Vysokovol'tnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0002-7688-7176
Contact information: Anna S. Sinyaeva, e-mail: anya.anyuta-07@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 27.02.2025.
Revised 07.03.2025.
Accepted 14.03.2025.
2. Nattel S., Heijman J., Zhou L., Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ Res. 2020;127(1):51–72. DOI: 10.1161/CIRCRESAHA.120.316363
3. Hindricks G., Potpara T., Dagres N. et al. Рекомендации ESC 2020 по диагностике и лечению пациентов с фибрилляцией предсердий, разработанные совместно с Европейской ассоциацией кардиоторакальной хирургии (EACTS). Российский кардиологический журнал. 2021;26:248. DOI: 10.15829/1560-4071-2021-4701Hindricks G., Potpara T., Dagres N. et al. ESC 2020 Guidelines for the diagnosis and Treatment of patients with atrial fibrillation, developed jointly with the European Association of Cardiothoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26:248 (in Russ.). DOI: 10.15829/1560-4071-2021-4701
4. Аванесян Г.А., Филатов А.Г. Биофизические аспекты удаления тканей миокарда при лечении пациентов с фибрилляцией предсердий. Анналы аритмологии. 2022;19(1):23–31. DOI: 10.15275/annaritmol.2022.1.4Avanesyan G.A., Filatov A.G. Biophysical aspects of myocardialtissue ablation in the treatment of patients with atrial fibrillation. Annaly Aritmologii. 2022;19(1):23–31 (in Russ.). DOI: 10.15275/annaritmol.2022.1.4
5. Schofield S.E., Parkinson J.R., Henley A.B. et al. Metabolic dysfunction following weight cycling in male mice. Int J Obes. 2017;41(3):402–411. DOI: 10.1038/ijo.2016.193
6. Schram-Serban C., Heida A., Roos-Serote M.C. et al. Heterogeneity in conduction underlies obesity-related atrial fibrillation vulnerability. Circ Arrhythm Electrophysiol. 2020;13(5):435–445. DOI: 10.1161/CIRCEP.119.008161
7. Li Y.-G., Xie P.-X., Alsheikh-Ali A.A. et al. The "obesity paradox" in patients withatrial fibrillation: Insights fromthe Gulf SAFE registry. Front Cardiovasc Med. 2022;9:1–9. DOI: 10.3389/fcvm.2022.1032633
8. Al Chekakie M.O., Akar J.G. Epicardial Fat and Atrial Fibrillation: A Review. J Atr Fibrillation. 2012;4(6):483. DOI: 10.4022/jafib.483
9. Hohl M., Lau D.H., Muller A. et al. Concomitant obesity andmetabolic syndrome add to the atrial arrhythmogenic phenotypein male hypertensive rats. J Am Heart Assoc. 2017;6(9):1–12. DOI: 10.1161/JAHA.117.006717
10. Verdecchia P., Angeli F., Reboldi G. Hypertension and atrialfibrillation: doubts and certainties from basic and clinicalstudies. Circ Res. 2018;122(2):352–368. DOI: 10.1161/CIRCRESAHA.117.311402
11. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptorblockade reduces new-onset atrial fibrillation and subsequentstroke compared to atenolol: the Losartan Intervention forEnd Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712–719. DOI: 10.1016/j.jacc.2004.10.068
12. Chumakova G., Gritsenko O., Gruzdeva O., Dyleva Y. Analysis of probable lipotoxic damage and myocardial fibrosis in epicardial obesity. Aging (Albany NY). 2021;13(11):14806–14815. DOI: 10.18632/aging.203148
13. Chao T.F., Liu C.J., Tuan T.C. et al. Lifetime risks, projected numbers, and adverse outcomes in asian patients with atrial fibrillation: a report from the Taiwan nationwide af cohort study. Chest. 2018;153(2):453–466. DOI: 10.1016/j.chest.2017.10.001
This work is licensed under a Creative Commons «Attribution» 4.0 License.
